Clinical Scorecard: Video: Letting Nature Lead – with John Maher
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Video
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Not described in the source.
Care Setting
Maher’s career combines academic research, clinical practice, and cell-therapy development through Leucid Bio.
Key Highlights
John Maher is a clinical immunologist, Scientific Founder and Chief Scientific Officer of Leucid Bio.
He leads the CAR Mechanics research group at King’s College London.
His work in CAR T-cell immunotherapy spans more than two decades, with a particular focus on developing treatments for solid tumors.
While working in Michel Sadelain’s laboratory at Memorial Sloan Kettering Cancer Center, Maher helped develop second-generation CAR technology incorporating CD28; the approach subsequently achieved clinical success in blood cancers.
The interview covers his route into immunology, contributions to CAR T development, and the scientific thinking behind his current research.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The source describes Maher’s work in CAR T-cell immunotherapy, particularly development of treatments for solid tumors; it does not specify a patient population.
The source describes his contribution to second-generation CAR technology incorporating CD28 and his current research, but gives no treatment protocol details.
Immunopeptidomics is helping researchers identify tumor-presented antigens that could inform the development of targeted cell therapies and personalized cancer vaccines